Is ProQR Therapeutics Stock a Good Investment?
ProQR Therapeutics Investment Advice | PRQR |
- Examine ProQR Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research ProQR Therapeutics' leadership team and their track record. Good management can help ProQR Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact ProQR Therapeutics' business and its evolving consumer preferences.
- Compare ProQR Therapeutics' performance and market position to its competitors. Analyze how ProQR Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if ProQR Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about ProQR Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in ProQR Therapeutics BV stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if ProQR Therapeutics BV is a good investment.
Sell | Buy |
Hold
Market Performance | Very Weak | Details | |
Volatility | Risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine ProQR Therapeutics Stock
Researching ProQR Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 14.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.31. ProQR Therapeutics had not issued any dividends in recent years.
To determine if ProQR Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding ProQR Therapeutics' research are outlined below:
| ProQR Therapeutics generated a negative expected return over the last 90 days | |
| ProQR Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 6.51 M. Net Loss for the year was (27.54 M) with profit before overhead, payroll, taxes, and interest of 18.39 M. | |
| ProQR Therapeutics has a frail financial position based on the latest SEC disclosures | |
| About 14.0% of the company outstanding shares are owned by corporate insiders |
ProQR Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in ProQR Therapeutics BV. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ProQR Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 21st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
ProQR Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 251 M.ProQR Therapeutics' profitablity analysis
The company has Profit Margin (PM) of (1.3) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.19) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.19.Determining ProQR Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if ProQR Therapeutics is a good buy. For example, gross profit margin measures ProQR Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of ProQR Therapeutics' profitability and make more informed investment decisions.
Basic technical analysis of ProQR Stock
As of the 22nd of January, ProQR Therapeutics holds the Risk Adjusted Performance of (0.09), coefficient of variation of (820.68), and Variance of 24.95. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of ProQR Therapeutics, as well as the relationship between them. Please check ProQR Therapeutics market risk adjusted performance and treynor ratio to decide if ProQR Therapeutics is priced some-what accurately, providing market reflects its current price of 2.23 per share. Please also confirm ProQR Therapeutics jensen alpha, which is currently at (0.65) to check out the company can sustain itself at a future point.ProQR Therapeutics' Outstanding Corporate Bonds
ProQR Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ProQR Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ProQR bonds can be classified according to their maturity, which is the date when ProQR Therapeutics BV has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Understand ProQR Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing ProQR Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (0.53) | |||
| Mean Deviation | 3.45 | |||
| Coefficient Of Variation | (820.68) | |||
| Standard Deviation | 4.99 | |||
| Variance | 24.95 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.65) | |||
| Total Risk Alpha | (0.78) | |||
| Treynor Ratio | (0.54) | |||
| Maximum Drawdown | 31.61 | |||
| Value At Risk | (7.63) | |||
| Potential Upside | 6.09 | |||
| Skewness | 0.3464 | |||
| Kurtosis | 4.0 |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (0.53) | |||
| Mean Deviation | 3.45 | |||
| Coefficient Of Variation | (820.68) | |||
| Standard Deviation | 4.99 | |||
| Variance | 24.95 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.65) | |||
| Total Risk Alpha | (0.78) | |||
| Treynor Ratio | (0.54) | |||
| Maximum Drawdown | 31.61 | |||
| Value At Risk | (7.63) | |||
| Potential Upside | 6.09 | |||
| Skewness | 0.3464 | |||
| Kurtosis | 4.0 |
Consider ProQR Therapeutics' intraday indicators
ProQR Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ProQR Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 76604.27 | |||
| Daily Balance Of Power | (0.56) | |||
| Rate Of Daily Change | 0.94 | |||
| Day Median Price | 2.34 | |||
| Day Typical Price | 2.3 | |||
| Price Action Indicator | (0.18) | |||
| Period Momentum Indicator | (0.14) |
ProQR Stock media impact
Far too much social signal, news, headlines, and media speculation about ProQR Therapeutics that are available to investors today. That information is available publicly through ProQR media outlets and privately through word of mouth or via ProQR internal channels. However, regardless of the origin, that massive amount of ProQR data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of ProQR Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of ProQR Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to ProQR Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive ProQR Therapeutics alpha.
ProQR Therapeutics Corporate Management
| Aniz MD | Chief Officer | Profile | |
| Domenico Valerio | Founder Board | Profile | |
| Sarah Kiely | Vice Communications | Profile | |
| Rene Beukema | Chief Corporate Devel. Officer, General Counsel, Corporate Secretary and Member of Management Board | Profile | |
| Sheila Sponselee | VP Operations | Profile | |
| Gerard Platenburg | Chief Innovation Officer | Profile |
Additional Tools for ProQR Stock Analysis
When running ProQR Therapeutics' price analysis, check to measure ProQR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProQR Therapeutics is operating at the current time. Most of ProQR Therapeutics' value examination focuses on studying past and present price action to predict the probability of ProQR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProQR Therapeutics' price. Additionally, you may evaluate how the addition of ProQR Therapeutics to your portfolios can decrease your overall portfolio volatility.